Screener
Charles River Laboratories CRL DSA — Acquisitions
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Charles River Laboratories’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001100682-26-000038
| Line item | RMS | DSA (1) | Manufacturing (2) | Total |
|---|---|---|---|---|
| December 27, 2025 | $510,844 | $1,678,518 | $574,891 | $2,764,253 |
| Acquisitions | — | 340,985 | — | 340,985 |
| Divestitures (3) | — | (46,653) | — | (46,653) |
| Foreign exchange | 257 | (14,376) | (4,434) | (18,553) |
| March 28, 2026 | $511,101 | $1,958,474 | $570,457 | $3,040,032 |
| (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010. | ||||
| (2) Manufacturing includes an accumulated impairment losses of $380 million, which was recognized in fiscal years 2024 and 2025. | ||||
| (3) DSA divestiture balance represents balances transferred to assets held for sale in connection with the European Discovery Divestiture. |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's DSA — acquisitions?
- Charles River Laboratories (CRL) reported DSA — acquisitions of $340.99M in Q1 2026.
- What does DSA — acquisitions mean?
- The total cash or equity consideration paid to acquire other businesses or assets integrated into this segment. This metric tracks the segment's inorganic growth strategy.
Ask your AI about Charles River Laboratories's dsa — acquisitions.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude